Screener
CG Oncology CGON EBIT
EBIT at other companies
Other financials
Where this comes from
Calculated from CG Oncology’s reported figures.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's EBIT?
- CG Oncology (CGON) reported EBIT of -$86.4M in Q2 2026.
- How has CG Oncology's EBIT changed year-over-year?
- CG Oncology's EBIT decreased by 77.3% year-over-year, from -$48.74M to -$86.4M.
- What is the long-term trend for CG Oncology's EBIT?
- Over 2 years (2023 to 2025), CG Oncology's EBIT has grown at a 85.5% compound annual growth rate (CAGR), from -$55.45M to -$190.77M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about CG Oncology's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude